Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2026-03-04 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
2025年年度独立董事述职报告（周建平已离任）
Board/Management Information Classification · 95% confidence The document is titled as the "2025 Annual Independent Director's Work Report" for Jiangsu Deyuan Pharmaceutical Co., Ltd. It is a detailed report by an independent director summarizing their duties, attendance, independence, and oversight activities during the 2025 fiscal year. The content includes descriptions of board meetings, committee participation, internal control reviews, related party transactions, and director remuneration. It is a formal report on the director's activities and governance oversight rather than a general annual report or financial statement. The document is not an announcement of a report but the report itself, and it focuses on board/management information specifically related to the independent director's role and duties. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 4358 characters, which is sufficient for a detailed report but not a full annual report or interim report. No financial statements or earnings highlights are present, so it is not 10-K or IR. It is not a proxy, voting result, or remuneration report. Hence, MANG is the best fit with high confidence.
2026-03-04 Chinese
2025年年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "Annual Equity Distribution Plan Announcement" for the year 2025 by Jiangsu Deyuan Pharmaceutical Co., Ltd. It discusses the company's profit distribution plan, including cash dividends and stock dividends, referencing audited financial results from the 2025 annual report. The document includes details on the dividend amount, stock issuance, board approval, and shareholder meeting requirements. It is an announcement of the company's dividend distribution plan rather than the full annual report or financial statements. The document length is 3599 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of "Notice of Dividend Amount" (DIV).
2026-03-04 Chinese
2025年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a '2025 Annual Performance Express Report' (年度业绩快报公告), which indicates it is a preliminary earnings announcement for the full year 2025. It contains key financial data such as revenue, net profit, earnings per share, and asset figures, but explicitly states that the data are preliminary and unaudited, with final audited figures to be disclosed in the formal annual report. The document is relatively short (2271 characters) and serves as an initial announcement of annual financial results rather than a full annual report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the correct classification is Earnings Release (ER). FY 2025
2026-02-04 Chinese
关于变更项目质量复核人的公告
Audit Report / Information Classification · 95% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding a change in the project quality reviewer for the company's 2025 financial audit. It references the appointment of the auditing firm Tianjian CPA and the replacement of the quality reviewer from Xiao Ruifeng to Zeng Lijuan. The document does not contain any financial statements or detailed audit results but is a notification about an internal change related to the audit process. It is not a full audit report, annual report, or financial statement. Given the nature of the content—an announcement about audit personnel changes—it fits best under Audit Report / Information (AR), which includes standalone audit reports and related audit information excluding full annual reports. The document length is short and focused on audit quality reviewer change, confirming it is not a full report or a regulatory filing. Therefore, the classification is AR with high confidence. FY 2025
2026-02-01 Chinese
第四届董事会第十七次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 17th meeting of the 4th Board of Directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and compliance with legal and regulatory requirements. The content focuses on board meeting decisions, including approval of related party transactions, and does not contain financial statements or detailed financial performance data. It is not an annual report, audit report, earnings release, or any other financial report. Instead, it is a Board/Management Information announcement regarding board meeting resolutions.
2025-12-25 Chinese
关于预计2026年日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected related party transactions for the year 2026 by Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes details about the nature of the transactions, the related party, pricing policies, and board resolutions approving the transactions. The document does not contain financial statements or comprehensive financial performance data. It is a regulatory announcement about related party transactions, which is a typical regulatory filing. The document length is 2604 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS).
2025-12-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.